ABBV · News · 20261031N
Competition and Market Position
AbbVie Inc. · 2026-10-31 · Importance 38 · Surprise 24 · In source text
AbbVie’s immunology products SKYRIZI and RINVOQ were key growth engines in Q3 2026, with reported sales of $5.78 billion and $2.71 billion, respectively. Their growth offset declining sales of the older immunology therapy Humira. The digest also describes newer launches as contributing to the product mix, while Imbruvica remained among the therapies facing pressure.
Key facts
- The FDA approved AbbVie’s Skyrizi for Crohn's disease. source
- AbbVie reported successful Phase 3 trials for lutikizumab in hidradenitis suppurativa. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | contingent | — | The FDA approved AbbVie’s Skyrizi for Crohn's disease. |